Accepted_test

Association between eNOS rs753482 polymorphism and abdominal obesity in patients with schizophrenia taking atypical antipsychotics

by Mednova I.A. | Pozhidaev I.V. | Paderina D.Z. | Petkun D.A. | Kornetova E.G. | Ivanova S.A. | Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia | Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia | Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia | Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia | Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia | Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia

Abstract ID: 474

Event: BGRS-abstracts

Sections: [Sym 4] Section “Human medical genomics/genetics”

Thus purpose of our study was to conduct an association analysis of the rs753482 eNOS polymorphism with abdominal obesity in patients with schizophrenia receiving antipsychotic therapy. The study included 485 patients with schizophrenia, of whom 197 persons received second-generation antipsychotics as basic therapy, and 288 people – first generation antipsychotics. Abdominal obesity was detected in 51.8% patients with schizophrenia who received atypical antipsychotics and in 43% people treated with typical antipsychotics. Using logistic regression including sex and age as covariates, an association of the rs753482 eNOS polymorphism with abdominal obesity was shown (p = 0.033). According to the results of the association analysis, it was found that the A allele is associated with an increased risk of abdominal obesity, and allele C – with a reduced risk (p = 0.016). In addition, patients with the AA genotype had a statistically significant increase in waist circumference compared to patients with the AC and CC genotypes (p = 0.05 and p = 0.039). In patients with the AA genotype, a statistically significant increase in visceral fat content was revealed compared with the data obtained in individuals with the AC genotype (p = 0.025). No statistically significant associations were found in patients taking first-generation antipsychotics. It seems promising to further study the molecular genetic features of the influence of anipsychotic therapy on the formation of metabolic disorders in order to implement an individual approach to therapeutic tactics. The study is supported by the Russian Science Foundation, grant number 23-75-10088.